Charles Schwab
MGX icon

Charles Schwab’s Metagenomi Therapeutics MGX Stock Holding History

Charles Schwab’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-65,753
Closed -$89.4K – 3595
2025
Q1 		$89.4K Hold
65,753
– – ﹤0.01% 3359
2024
Q4 		$237K Buy
65,753
+50,974
+345% +$123K ﹤0.01% 3297
2024
Q3 		$32.1K Sell
14,779
-30,332
-67% -$105K ﹤0.01% 3459
2024
Q2 		$184K Buy
45,111
+14,963
+50% +$103K ﹤0.01% 3446
2024
Q1 		$318K Buy
+30,148
New +$347K ﹤0.01% 3165

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab's MGX Position: Q2 2025 in Review

Charles Schwab sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 65,753 shares — an estimated $89.4K sold.

Charles Schwab first reported a position in MGX in Q1 2024 and held it in 5 quarters. The position peaked at $318K in Q1 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Charles Schwab reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 65,753 Metagenomi Therapeutics shares in Q2 2025, an estimated $89.4K.
  • Charles Schwab first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 5 quarters.
  • Charles Schwab's Metagenomi Therapeutics position peaked at $318K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.